Tokyo, Japan

Shinnosuke Hosoda

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Teijin Pharma Limited. Active years: 2020.

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shinnosuke Hosoda: Innovator in Pharmaceutical Chemistry

Introduction

Shinnosuke Hosoda is a prominent inventor based in Tokyo, Japan. He is known for his contributions to pharmaceutical chemistry, particularly in the development of compounds that regulate androgen receptor activity. His innovative work has led to the filing of a significant patent that showcases his expertise in this field.

Latest Patents

Shinnosuke Hosoda holds a patent for an aminoazole derivative, which is a compound designed to regulate the activity of an androgen receptor. The patent describes a medically acceptable salt of the compound, represented by a complex formula involving various chemical groups. This invention has the potential to impact therapeutic approaches in medicine.

Career Highlights

Shinnosuke Hosoda is currently employed at Teijin Pharma Limited, a company recognized for its advancements in pharmaceutical products. His role at the company allows him to apply his knowledge and skills in developing innovative solutions for health-related challenges.

Collaborations

Throughout his career, Shinnosuke has collaborated with notable colleagues, including Gen Unoki and Hidekazu Watanabe. These partnerships have contributed to the advancement of research and development in their respective fields.

Conclusion

Shinnosuke Hosoda's work exemplifies the spirit of innovation in pharmaceutical chemistry. His patent for an aminoazole derivative highlights his commitment to advancing medical science. His contributions are significant in the ongoing quest for effective therapeutic solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…